Similarly, the levels of serum CTSS are positively correlated with the degrees of angiogenesis and inflammation in patients with ESRD (29) while treatment with the CTSS inhibitor can reduce cardiovascular inflammation in patients with CKD (30). Here, CTSS is linked to chronic kidney disease.